福瑞股份(300049) - 2025 Q2 - 季度业绩预告

Inner Mongolia Furui Medical Technology Co., Ltd. 2025 Semi-Annual Performance Forecast This report provides a preliminary forecast for the company's performance in the first half of 2025, highlighting key financial indicators and factors influencing changes Key Performance Indicators Forecast The company anticipates a trend of "rising revenue, declining profit" for the first half of 2025, with net profit attributable to shareholders expected to decrease by 20% to 34% 2025 H1 Performance Forecast | Item | Current Period (2025 H1) | Prior Period (2024 H1) | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | Profit: 50.00 million CNY - 60.00 million CNY | Profit: 75.36 million CNY | | YoY Change | Decrease: 34% - 20% | - | | Net Profit After Non-Recurring Items | Profit: 51.50 million CNY - 61.50 million CNY | Profit: 74.46 million CNY | | YoY Change | Decrease: 31% - 17% | - | Analysis of Performance Changes The decline in net profit is primarily due to non-operating factors, including a significant increase in equity incentive expenses and foreign exchange losses, despite steady growth in core businesses - Excluding the impact of equity incentive expenses and foreign exchange gains/losses, net profit attributable to shareholders for the reporting period is estimated to be 75.00-85.00 million CNY, representing a year-over-year increase of approximately 5%-19%, reflecting healthy growth in core operations[6] Core Business Performance During the reporting period, the company's core businesses maintained growth, with medical device business serving as the primary growth engine, while pharmaceutical and medical services businesses also developed steadily Performance by Business Segment | Business Segment | Estimated Operating Revenue (million CNY) | YoY Growth | Estimated Net Profit (million CNY) | | :--- | :--- | :--- | :--- | | Medical Devices | 470 - 490 | 11% - 16% | 73 - 78 | | Pharmaceuticals and Medical Services | 225 - 240 | 3% - 10% | 35 - 40 | Impact of Non-Operating Factors The decline in net profit is primarily attributed to a significant year-over-year increase in equity incentive share-based payment expenses and foreign exchange losses due to currency depreciation Comparison of Major Non-Recurring Items | Impact Item | Current Period (2025 H1) | Prior Period (2024 H1) | | :--- | :--- | :--- | | Equity Incentive Expenses | Approx. 12.44 million CNY | 5.18 million CNY | | Foreign Exchange Gains/Losses | Loss approx. 15.24 million CNY | Gain 8.57 million CNY | Important Disclosures and Risk Warnings The company clarifies that this performance forecast is based on preliminary calculations and has not been audited, advising investors to exercise caution due to inherent investment risks - This performance forecast is a preliminary estimate by the company's finance department and has not been audited[4] - Non-recurring gains and losses are expected to have an impact of approximately 1.50 million CNY on net profit for the first half of 2025[7] - The company advises that final specific data will be detailed in the 2025 semi-annual report, urging investors to make cautious decisions and be aware of investment risks[7]